Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments
- 4 May 2007
- journal article
- review article
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 9 (12), 1-24
- https://doi.org/10.1017/s1462399407000312
Abstract
Nasopharyngeal carcinoma (NPC) is a prevalent tumour in southern China and southeast Asia, particularly in the Cantonese population, where its incidence has remained high for decades. Recent studies have demonstrated that the aetiology of NPC is complex, involving multiple factors including genetic susceptibility, infection with the Epstein–Barr virus (EBV) and exposure to chemical carcinogens. During development of the disease, viral infection and multiple somatic genetic and epigenetic changes synergistically disrupt normal cell function, thus contributing to NPC pathogenesis. NPC is highly radiosensitive and chemosensitive, but treatment of patients with locoregionally advanced disease remains problematic. New biomarkers for NPC, including EBV DNA copy number or methylation of multiple tumour suppressor genes, which can be detected in serum and nasopharyngeal brushings, have been developed for the molecular diagnosis of this tumour. Meanwhile, new therapeutic strategies such as intensity-modulated radiation therapy and immuno- and epigenetic therapies might lead to more specific and effective treatments.Keywords
This publication has 100 references indexed in Scilit:
- Adulthood consumption of preserved and nonpreserved vegetables and the risk of nasopharyngeal carcinoma: A systematic reviewInternational Journal of Cancer, 2006
- Dual regulation of the ΔNp63 transcriptional activity by ΔNp63 in human nasopharyngeal carcinoma cellBiochemical and Biophysical Research Communications, 2006
- Conventional and array-based comparative genomic hybridization analysis of nasopharyngeal carcinomas from the Mediterranean areaCancer Genetics and Cytogenetics, 2005
- A Conditionally Replicating Adenovirus for Nasopharyngeal Carcinoma Gene TherapyMolecular Therapy, 2004
- Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cellsCarcinogenesis: Integrative Cancer Research, 2004
- Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20‐year period (1980–99): An encouraging reduction in both incidence and mortalityInternational Journal of Cancer, 2002
- High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?Oncogene, 2000
- Epstein–Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinomaSeminars in Cancer Biology, 1996
- Loss of heterozygosity on the short arm of chromosome 3 in nasopharyngeal carcinomaCancer Genetics and Cytogenetics, 1991
- The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomasEuropean Journal of Cancer and Clinical Oncology, 1987